1. Home
  2. YSXT vs AVTX Comparison

YSXT vs AVTX Comparison

Compare YSXT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YSXT
  • AVTX
  • Stock Information
  • Founded
  • YSXT 2011
  • AVTX 2011
  • Country
  • YSXT China
  • AVTX United States
  • Employees
  • YSXT N/A
  • AVTX N/A
  • Industry
  • YSXT Automotive Aftermarket
  • AVTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • YSXT Consumer Discretionary
  • AVTX Health Care
  • Exchange
  • YSXT Nasdaq
  • AVTX Nasdaq
  • Market Cap
  • YSXT 104.6M
  • AVTX 90.9M
  • IPO Year
  • YSXT 2024
  • AVTX 2015
  • Fundamental
  • Price
  • YSXT $2.70
  • AVTX $8.33
  • Analyst Decision
  • YSXT
  • AVTX Strong Buy
  • Analyst Count
  • YSXT 0
  • AVTX 4
  • Target Price
  • YSXT N/A
  • AVTX $33.00
  • AVG Volume (30 Days)
  • YSXT 256.5K
  • AVTX 145.5K
  • Earning Date
  • YSXT 01-01-0001
  • AVTX 11-07-2024
  • Dividend Yield
  • YSXT N/A
  • AVTX N/A
  • EPS Growth
  • YSXT N/A
  • AVTX N/A
  • EPS
  • YSXT 0.21
  • AVTX N/A
  • Revenue
  • YSXT $58,546,729.00
  • AVTX $820,000.00
  • Revenue This Year
  • YSXT N/A
  • AVTX N/A
  • Revenue Next Year
  • YSXT N/A
  • AVTX N/A
  • P/E Ratio
  • YSXT $13.73
  • AVTX N/A
  • Revenue Growth
  • YSXT 18.92
  • AVTX N/A
  • 52 Week Low
  • YSXT $2.60
  • AVTX $3.95
  • 52 Week High
  • YSXT $5.52
  • AVTX $34.46
  • Technical
  • Relative Strength Index (RSI)
  • YSXT N/A
  • AVTX 32.54
  • Support Level
  • YSXT N/A
  • AVTX $8.01
  • Resistance Level
  • YSXT N/A
  • AVTX $9.41
  • Average True Range (ATR)
  • YSXT 0.00
  • AVTX 1.00
  • MACD
  • YSXT 0.00
  • AVTX -0.02
  • Stochastic Oscillator
  • YSXT 0.00
  • AVTX 8.02

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Share on Social Networks: